Combinations

Use of a combination of compounds for treating a disease or condition, wherein the combination includes an effective amount of Compound (C), or a pharmaceutically acceptable salt thereof, and an effective amount of one or more of Compound (B), or a pharmaceutically acceptable salt thereof, wherein:

• the Compound (C) has the structure:
• wherein:
• X1, Y1 and Z1 are each independently C or N;
• with the first proviso that at least one of X1, Y1 and Z1 is N;
• with the second proviso that each of X1, Y1 and Z1 is uncharged;
• with third proviso that two of the dotted lines indicate double bonds;
• with the fourth proviso that the valencies of X1, Y1 and Z1 can be each independently satisfied by attachment to a substituent selected from H and R12;
• X2 is O;
• A1 is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;
• R1 is selected from the group consisting of an optionally substituted C1-6 alkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(C1-6 alkyl), an optionally substituted cycloalkenyl(C1-6 alkyl), an optionally substituted aryl(C1-6 alkyl), an optionally substituted heteroaryl(C1-6 alkyl) and an optionally substituted heterocyclyl(C1-6 alkyl);
• R2 and R3 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl and an optionally substituted C1-6 haloalkyl;
• or R2 and R3 together with the carbon to which R2 and R3 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
• R4 and R5 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl and an optionally substituted C1-6 haloalkyl;
• or R4 and R5 together with the carbon to which R4 and R5 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
• R6, R7, R8 and R9 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted haloalkyl, an optionally substituted mono-substituted amine, and an optionally substituted di-substituted amine;
• R10 is hydrogen, halogen, an optionally substituted alkyl, or an optionally substituted cycloalkyl;
• R11 is hydrogen;
• and
• R12 is hydrogen, halogen, an optionally substituted C1-3 alkyl, an optionally substituted C1-3 haloalkyl or an optionally substituted C1-3 alkoxy;
• provided that the Compound (C) cannot be
• or a pharmaceutically acceptable salt thereof;
• and
• the one or more of Compound (B) is selected from the group consisting of a CDK4/6 inhibitor, a selective aromatase inhibitor, a non-selective aromatase inhibitor, a mTOR inhibitor, a PI3K inhibitor, an ERK or a MEK inhibitor, AKT inhibitor, BET inhibitor and Aurora inhibitor, or a pharmaceutically acceptable salt of any of the foregoing;
• wherein the CDK4/6 inhibitor is selected from the group consisting of:
• or a pharmaceutically acceptable salt of any of the foregoing;
• wherein the selective aromatase inhibitor is selected from the group consisting of
• or a pharmaceutically acceptable salt of any of the foregoing;
• wherein the non-selective aromatase inhibitor is selected from the group consisting of
• or a pharmaceutically acceptable salt of any of the foregoing;
• wherein the mTOR inhibitor is selected from the group consisting of
• or a pharmaceutically acceptable salt of any of the foregoing;
• wherein the PI3K inhibitor is selected from the group consisting of
• or a pharmaceuticallyacceptable salt of any of the foregoing;
• wherein the ERK or the MEK inhibitor is selected from the group consisting of
• or a pharmaceutically acceptable salt of any of the foregoing;
• wherein the AKT inhibitor is selected from the group consisting of
• or a pharmaceutically acceptable salt of any of the foregoing;
• wherein the BET inhibitor is selected from the group consisting of
• or a pharmaceutically acceptable salt of any of the foregoing;
• and
• wherein the Aurora inhibitor is selected from the group consisting of
• or a pharmaceutically acceptable salt of any of the foregoing.